Pro Share Advisors LLC Akebia Therapeutics, Inc. Transaction History

Pro Share Advisors LLC

$39.7 Billion
Q3 2024

A detailed history of Pro Share Advisors LLC transactions in Akebia Therapeutics, Inc. stock. As of the latest transaction made, Pro Share Advisors LLC holds 39,308 shares of AKBA stock, worth $70,361. This represents 0.0% of its overall portfolio holdings.

Number of Shares

39,308

Holding current value

$70,361

% of portfolio

0.0%

23 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 13, 2024	BUY	$0.94 - $1.55 $36,949 - $60,927	39,308 New	39,308 $51,000
Q3 2022 Nov 04, 2022	BUY	$0.3 - $0.46 $351 - $539	1,172 Added 8.2%	15,465 $5,000
Q2 2022 Aug 01, 2022	SELL	$0.32 - $0.67 $11,684 - $24,464	-36,514 Reduced 71.87%	14,293 $5,000
Q1 2022 May 10, 2022	SELL	$0.72 - $2.93 $8,592 - $34,966	-11,934 Reduced 19.02%	50,807 $36,000
Q4 2021 Feb 08, 2022	BUY	$2.26 - $3.34 $7,021 - $10,377	3,107 Added 5.21%	62,741 $142,000
Q3 2021 Nov 12, 2021	SELL	$2.35 - $3.88 $24,881 - $41,081	-10,588 Reduced 15.08%	59,634 $172,000
Q2 2021 Aug 13, 2021	BUY	$2.83 - $4.2 $30,238 - $44,877	10,685 Added 17.95%	70,222 $266,000
Q1 2021 May 14, 2021	BUY	$2.92 - $5.06 $16,062 - $27,835	5,501 Added 10.18%	59,537 $202,000
Q4 2020 Feb 09, 2021	BUY	$2.22 - $3.78 $29,721 - $50,606	13,388 Added 32.94%	54,036 $151,000
Q3 2020 Nov 13, 2020	BUY	$2.39 - $13.08 $831 - $4,551	348 Added 0.86%	40,648 $102,000
Q2 2020 Aug 03, 2020	BUY	$6.67 - $13.58 $113,396 - $230,873	17,001 Added 72.97%	40,300 $547,000
Q1 2020 May 15, 2020	SELL	$4.1 - $10.24 $75,546 - $188,682	-18,426 Reduced 44.16%	23,299 $177,000
Q4 2019 Feb 12, 2020	SELL	$3.16 - $6.73 $12,327 - $26,253	-3,901 Reduced 8.55%	41,725 $264,000
Q3 2019 Nov 12, 2019	BUY	$3.55 - $5.4 $7,565 - $11,507	2,131 Added 4.9%	45,626 $179,000
Q2 2019 Aug 13, 2019	SELL	$4.1 - $8.05 $21,939 - $43,075	-5,351 Reduced 10.95%	43,495 $211,000
Q1 2019 May 15, 2019	BUY	$5.41 - $8.73 $110,888 - $178,938	20,497 Added 72.3%	48,846 $400,000
Q4 2018 Feb 14, 2019	SELL	$5.39 - $9.15 $5,815 - $9,872	-1,079 Reduced 3.67%	28,349 $157,000
Q3 2018 Nov 14, 2018	SELL	$7.44 - $10.65 $8,332 - $11,928	-1,120 Reduced 3.67%	29,428 $260,000
Q2 2018 Aug 13, 2018	BUY	$9.15 - $11.34 $27,193 - $33,702	2,972 Added 10.78%	30,548 $305,000
Q1 2018 May 14, 2018	SELL	$9.53 - $15.68 $43,209 - $71,093	-4,534 Reduced 14.12%	27,576 $263,000
Q4 2017 Feb 14, 2018	BUY	$14.24 - $19.59 $35,286 - $48,544	2,478 Added 8.36%	32,110 $477,000
Q3 2017 Nov 13, 2017	BUY	$13.06 - $19.67 $83,897 - $126,360	6,424 Added 27.68%	29,632 $583,000
Q2 2017 Aug 11, 2017	BUY	N/A	23,208	23,208 $333,000

Others Institutions Holding AKBA

# of Institutions

121

Shares Held

54.8M

Call Options Held

291K

Put Options Held

179K

View Full List

About Akebia Therapeutics, Inc.

Ticker AKBA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 183,848,992
Market Cap $329M
Description
Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) ...

More about AKBA

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Pro Share Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Pro Share Advisors LLC with notifications on news.

Account

Pro Share Advisors LLC Akebia Therapeutics, Inc. Transaction History